Immunotherapy and chemotherapy join forces to fight recurrent ovarian cancer
NCT ID NCT04387227
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes 22 patients whose cancer had no visible tumors on scans but had rising CA-125 levels. The goal is to see if this combination can delay or stop the cancer from becoming detectable on imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (immunotherapy) and carboplatin (chemotherapy)
- What this could lead to
- If it works, this combination could delay or prevent the return of ovarian cancer after it is first detected by a blood test, potentially extending the time before tumors become visible on scans.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. The combination may cause side effects like fatigue, low blood counts, or immune-related reactions, and it may not prevent progression in all cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- Engineered immune cells target Hard-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup